Latigo Biotherapeutics
Clinical trials sponsored by Latigo Biotherapeutics, explained in plain language.
-
New pain drug candidate enters first human safety tests
Knowledge-focused Recruiting nowThis early-stage study tests a new oral drug, LTG-321, in 236 healthy adults aged 18 to 55 to see if it is safe and how the body processes it. Some participants will also take a cold pressor test to measure pain tolerance. The study does not aim to treat any disease, but to gathe…
Phase: PHASE1 • Sponsor: Latigo Biotherapeutics • Aim: Knowledge-focused
Last updated May 17, 2026 06:51 UTC
-
New drug LTG-001: first human tests begin for safety
Knowledge-focused Recruiting nowThis early-stage study tests a new drug, LTG-001, in 204 healthy adults aged 18 to 55. The goal is to check its safety, side effects, and how the body processes it when taken by mouth or through a vein. No treatment is given—this is purely to gather information for future researc…
Phase: PHASE1 • Sponsor: Latigo Biotherapeutics • Aim: Knowledge-focused
Last updated May 17, 2026 06:50 UTC